Tubercular involvement of pancreas is rare. It presents as a focal lesion of pancreas on cross sectional imaging. Endosonography with fine-needle aspiration (EUS-FNA) is important for a effectively timed presurgical evaluation.
A retrospective evaluation was carried out on 117 circumstances of pancreatic focal mass current course of EUS-FNA at our institution over a interval of three years, and 5 circumstances with pancreatic tuberculosis (TB) had been detected.
The medical presentation numerous from obstructive jaundice, recurrent acute pancreatitis to incidentaloma of pancreas. All victims acquired antitubercular treatment and had been adopted up for on the very least 6 months.
In conclusion, pancreatic tuberculosis is a differential of a pancreatic focal lesion and EUS-FNA is the technique for evaluation of this case that can obviate surgical exploration.
Mycobacterium tuberculosis-Explicit T Cell Purposeful, Memory, and Activation Profiles in QuantiFERON-Reverters Are Fixed With Managed An infectioN
Reversion of immune sensitization exams for Mycobacterium tuberculosis (M.tb) an an infection, resembling interferon-gamma launch assays or tuberculin pores and pores and skin test, has been reported in quite a few analysis.
We hypothesized that QuantiFERON-TB Gold (QFT) reversion is said to a decline of M.tb-specific helpful T cell responses, and a particular pattern of T cell and innate responses as compared with persistent QFT+ and QFT- individuals.
We in distinction groups of healthful adolescents (n=~30 each), outlined by 4, 6-monthly QFT exams: reverters (QFT+/+/-/-), non-converters (QFT-/-/-/-) and persistent positives (QFT+/+/+/+).
We stimulated peripheral blood mononuclear cells with M.tb antigens (M.tb lysate; CFP-10/ESAT-6 and EspC/EspF/Rv2348 peptide swimming swimming pools) and measured M.tb-specific adaptive T cell memory, activation, and helpful profiles; along with helpful innate (monocytes, pure killer cells), donor-unrestricted T cells (DURT: γδ T cells, mucosal-associated invariant T and pure killer T-like cells) and B cells by motion cytometry.
Projection to latent home discriminant analysis was utilized to seek out out choices that most interesting distinguished between QFT reverters, non-converters and persistent positives. No longitudinal modifications in immune responses to M.tb had been seen upon QFT reversion.
M.tb-specific Th1 responses detected in reverters had been of intermediate magnitude, bigger than responses in QFT non-converters and reduce than responses in persistent positives.
About one third of reverters had a robust response to CFP-10/ESAT-6. Amongst these with measurable responses, lower proportions of TSCM (CD45RA+CCR7+CD27+) and early differentiated (CD45RA-) IFN-γ-TNF+IL-2- M.tb lysate-specific CD4+ cells had been seen in reverters in distinction with non-converters.
Conversely, bigger proportions of early differentiated and reduce proportions of effector (CD45RA-CCR7-) CFP10/ESAT6-specific Th1 cells had been seen in reverters as compared with persistent-positives. No variations in M.tb-specific innate, DURT or B cell helpful responses had been seen between the groups.
Statistical modelling misclassified the overwhelming majority of reverters as non-converters additional usually than that they had been appropriately categorised as reverters or misclassified as persistent positives.
These findings suggest that QFT reversion occurs in a heterogeneous group of individuals with low M.tb-specific T cell responses. In some individuals QFT reversion may finish end result from assay variability, whereas in others the magnitude and differentiation standing of M.tb-specific Th1 cells are in line with well-controlled M.tb an an infection.
Disseminated Tuberculosis Associated With Adalimumab Treatment
Therapeutic blockade of tumour necrosis difficulty alpha (anti-TNF-α) is the mainstay remedy of quite a few rheumatologic sicknesses. They’re unfrequently associated to opportunistic infections and latent tuberculosis (TB) screening is paramount sooner than immunosuppression.
A 62-year-old man with psoriatic arthritis was beneath remedy with adalimumab for over 5 years. The screening for latent tuberculosis an an infection (LTBI) earlier to the start of immunosuppression was detrimental, and a subsequent interferon gamma launch assay 4 years later was moreover detrimental.
He launched inside the emergency division complaining of asthenia, anorexia, fever, night sweats and weight discount for over 5 months. He moreover complained of memory loss, no matter his common cognitive and neurological examination.
After an exhaustive workup, he was recognized with a disseminated tuberculosis (cerebral, pulmonary and peritoneal) and dealt with accordingly. TB evaluation stays troublesome in positive situations.
Latent TB screening exams may lack sensitivity and immunosuppressive treatment will improve the hazard of disseminated an an infection. We discuss in regards to the workup and administration of a central nervous system disseminated TB related to adalimumab treatment.
Distinction-Enhanced Ultrasound Imaging Choices of Focal Splenic Tuberculosis
BACKGROUND The aim of this look at was to characterize the contrast-enhanced ultrasound imaging choices of focal splenic tuberculosis. MATERIAL AND METHODS We retrospectively analyzed the usual ultrasound (US) and contrast-enhanced ultrasound (CEUS) imaging choices of 22 victims with splenic TB confirmed by surgical histopathology or biopsy.
RESULTS Typical US demonstrated that 15 of the 22 victims had a single lesion, whereas 7 had quite a few lesions. The utmost diameter of the lesions ranged from 1.zero to a few.7 cm. Of the 22, 17 had been detected with hypoecho and 5 had been detected with superior echo by typical US. Seven (7/22) had been detected with blood motion alerts by coloration Doppler motion image (CDFI).
CUES demonstrated that 18 circumstances (81.8%, 18/22) began to bolster inside the arterial part, principally adopted by gradual wash-out inside the intermediate or late parenchymal part, and 4 (18.2%, 4/22) launched with non-enhancement all through all phases.
The enhancement patterns had been categorized into 4 kinds: Variety I, homogeneous enhancement (2/22); Variety II, rim-like enhancement (12/22); Variety III, septation-like enhancement (4/22); and Variety IV, non-enhancement (4/22).
CONCLUSIONS CEUS confirmed that splenic TB lesions had been enhanced inside the arterial part, adopted by gradual washed out or persistent enhancement inside the intermediate and late parenchymal phases.
The rim- or septation-like enhancement may be helpful for diagnosing splenic TB. The splenic lesions presenting spherical hypoecho by typical US and full non-enhancement by CEUS are extraordinarily suspicious of splenic TB.
A high-frequency single nucleotide polymorphism inside the MtrB sensor kinase in medical strains of Mycobacterium tuberculosis alters its biochemical and physiological properties
The DNA polymorphisms current in medical strains of Mycobacterium tuberculosis drive altered physiology, virulence, and pathogenesis in them.
Although the lineages of these medical strains might be traced once more to frequent ancestor/s, there exists a plethora of distinction between them, in distinction to individuals who have developed inside the laboratory.
We decide a mutation present in ~80% of medical strains, which maps inside the HATPase space of the sensor kinase MtrB and alters kinase and phosphatase actions, and impacts its physiological perform.
The modifications conferred by the mutation had been probed by in-vitro biochemical assays which revealed modifications in signaling properties of the sensor kinase. These modifications moreover impact bacterial cell division costs, measurement and membrane properties.
 A549 HCP Control Antigen |
|
F237 |
Cygnus Technologies |
50 ul |
EUR 308.4 |
|
|
|
Description: A549 HCP Control Antigen by Cygnus Technologies is available in Europe via Gentaur. |
 HCV NS3 1359-1456aa antigen |
|
00154-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
|
|
Description: HCV NS3 1359-1456aa antigen. The protein contains immunodominant regions (1359-1456aa). available genotypes: 1a, 1b, 2b, 3, 4, 5, 6 |
HCV NS3 1359-1456aa antigen |
|
00154-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
|
|
Description: HCV NS3 1359-1456aa antigen. The protein contains immunodominant regions (1359-1456aa). available genotypes: 1a, 1b, 2b, 3, 4, 5, 6 |
) Antigen 85-A Antibody (HRP) |
|
20-abx109227 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
|
) Cancer Antigen 125 Antigen (Ascites Fluid) |
|
VAng-Cr3870-10kU |
Creative Biolabs |
10 kU |
EUR 1132.8 |
|
Description: Cancer Antigen 125 Antigen, Host/Source: Ascites Fluid. The purity is ≥ 95% by SDS-PAGE. |
 A549 HCP Antigen Concentrate |
|
F233G |
Cusabio |
200 ul |
EUR 540 |
|
|
|
Description: A549 HCP Antigen Concentrate by Cygnus Technologies is available in Europe via Gentaur. |
) Antigen 85-A Antibody (FITC) |
|
20-abx107809 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
|
 antigen) Human carcinoembryonic antigen (CEA) antigen |
|
CEA15-N-100 |
Alpha Diagnostics |
100 ug |
EUR 270 |
 Antibody) Antigen 85-A (Ag85A) Antibody |
|
20-abx110661 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
|
) Antigen 85-A Antibody (Biotin) |
|
20-abx106397 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
|
) Cancer Antigen 125 Antigen (Human Adenocarcinoma) |
|
VAng-Cr3868-10kU |
Creative Biolabs |
10 kU |
EUR 505.2 |
|
Description: Cancer Antigen 125 Antigen, Host/Source: Human Adenocarcinoma. The purity is detected by salt extraction and chromatography. |
) Cancer Antigen CEA Antigen (Human Fluids) |
|
VAng-Wyb8644-inquire |
Creative Biolabs |
inquire |
Ask for price |
|
Description: Carcinoembryonic Antigen, Calibrator Grade, Cancer antigen from Human Fluids, 1.13 mg/mL. |
) Cancer Antigen 19-9 Antigen (Liver Carcinoma) |
|
VAng-Cr3873-10kU |
Creative Biolabs |
10 kU |
EUR 472.8 |
|
Description: Cancer Antigen 19-9 Antigen, Host/Source: Liver Carcinoma. The purity is detected by gel filtration and ion-exchange chromatography. It is tested negative for HBsAg, antibodies to HCV and HIV 1/2. |
 Prostate Specific Antigen Std Grade Antigen |
|
VAng-Cr3891-1mg |
Creative Biolabs |
1 mg |
EUR 604.8 |
|
Description: Prostate Specific Antigen Std Grade Antigen, Host/Source: Human Seminal Fluid. The purity is detected by salt precipitation. |
 HBV surface recombinant antigen HBsAg antigen |
|
00123-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
|
|
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant High purity |
HBV surface recombinant antigen HBsAg antigen |
|
00123-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
|
|
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant High purity |
HBV surface recombinant antigen HBsAg antigen |
|
00124-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
|
|
Description: HBV surface recombinant antigen HBsAg antigen 31 kDa E. coli recombinant |
HBV surface recombinant antigen HBsAg antigen |
|
00124-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
|
|
Description: HBV surface recombinant antigen HBsAg antigen 31 kDa E. coli recombinant |
 (> 90%)) Cancer Antigen 125 Antigen (Human Adenocarcinoma) (> 90%) |
|
VAng-Cr3869-25kU |
Creative Biolabs |
25 kU |
EUR 967.2 |
|
Description: Cancer Antigen 125 Antigen, Host/Source: Human Adenocarcinoma. The purity is> 90% by SDS-PAGE. Matched Pair: HM183, HM184, HM185, HM186. |
) Cancer Antigen AFP Antigen (Human Cord Blood) |
|
VAng-Wyb8624-inquire |
Creative Biolabs |
inquire |
Ask for price |
|
Description: Alpha Fetoprotein (66 kDa), Cancer antigen from Human Cord Blood, 1.73 mg/mL. |
) Cancer Antigen CA-125 Antigen (Human Fluids) |
|
VAng-Wyb8639-inquire |
Creative Biolabs |
inquire |
Ask for price |
|
Description: CA-125, Calibrator Grade, cancer antigen from Human Fluids, 53.26 KU/mL. |
 (> 90%)) Cancer Antigen 19-9 Antigen (Liver Carcinoma) (> 90%) |
|
VAng-Cr3875-25kU |
Creative Biolabs |
25 kU |
EUR 885.6 |
|
Description: Cancer Antigen 19-9 Antigen, Host/Source: Liver Carcinoma. The purity is> 90% by SDS-PAGE. It is tested negative for HBsAg, antibodies to HCV and HIV 1/2. |
 CD9 Antigen |
|
E6TA00101 |
EnoGene |
0.1mg |
EUR 411.6 |
 MPO Antigen |
|
E61A00501 |
EnoGene |
1mg |
EUR 1230 |
 HAV Antigen |
|
E61H00101 |
EnoGene |
1mg |
EUR 733.2 |
 HBS Antigen |
|
E61H00301 |
EnoGene |
1mg |
EUR 374.4 |
HBS Antigen |
|
E61H00302 |
EnoGene |
1mg |
EUR 374.4 |
 HBe Antigen |
|
E61H00501 |
EnoGene |
1mg |
EUR 463.2 |
 HBc Antigen |
|
E61H00701 |
EnoGene |
1mg |
EUR 463.2 |
 AFP Antigen |
|
E62C002 |
EnoGene |
20ug |
EUR 458.4 |
 HCG Antigen |
|
E62C004 |
EnoGene |
100ug |
EUR 458.4 |
 CEA Antigen |
|
E62C010 |
EnoGene |
20ug |
EUR 458.4 |
 CK8 Antigen |
|
E62C02001 |
EnoGene |
20ug |
EUR 458.4 |
 CRP Antigen |
|
E64C00501 |
EnoGene |
1mg |
EUR 840 |
CRP Antigen |
|
E64C00502 |
EnoGene |
1mg |
EUR 840 |
 BSA Antigen |
|
IM112 |
Cygnus Technologies |
1 ml |
EUR 342 |
|
|
|
Description: BSA Antigen by Cygnus Technologies is available in Europe via Gentaur. |
 HSA Antigen |
|
IM118 |
Cygnus Technologies |
1 ml |
EUR 342 |
|
|
|
Description: HSA Antigen by Cygnus Technologies is available in Europe via Gentaur. |
 CDV Antigen |
|
VAng-Lsx0016-1mg |
Creative Biolabs |
1 mg |
EUR 1688.4 |
|
Description: Canine Distemper Virus Antigen from SL-29 cells. |
 CD63 Antigen |
|
E6TA00102 |
EnoGene |
0.1mg |
EUR 411.6 |
 CD81 Antigen |
|
E6TA00103 |
EnoGene |
0.1mg |
EUR 411.6 |
 S100 Antigen |
|
E62B003 |
EnoGene |
20ug |
EUR 458.4 |
 CA50 Antigen |
|
E62C009 |
EnoGene |
10KU |
EUR 458.4 |
 CK18 Antigen |
|
E62C02101 |
EnoGene |
20ug |
EUR 458.4 |
 CK20 Antigen |
|
E62C02201 |
EnoGene |
20ug |
EUR 458.4 |
 GP73 antigen |
|
E62C02701 |
EnoGene |
20ug |
EUR 458.4 |
 TP17 Antigen |
|
E62H00701 |
EnoGene |
100ug |
EUR 458.4 |
 TP47 Antigen |
|
E62H00702 |
EnoGene |
100ug |
EUR 458.4 |
 cTnI antigen |
|
E64C00101 |
EnoGene |
100ug |
EUR 508.8 |
cTnI antigen |
|
E64C00102 |
EnoGene |
100ug |
EUR 733.2 |
 cTnC antigen |
|
E64C01301a |
EnoGene |
20ug |
EUR 411.6 |
 sST2 antigen |
|
E64C01501 |
EnoGene |
20ug |
EUR 411.6 |
 PAPP Antigen |
|
E64D00101 |
EnoGene |
100ug |
EUR 1425.6 |
PAPP Antigen |
|
E64D00102 |
EnoGene |
1mg |
EUR 5910 |
 HCV NS4 1916-1947aa recombinant antigen |
|
00156-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
|
|
Description: HCV NS4 1916-1947aa recombinant antigen. |
HCV NS4 1916-1947aa recombinant antigen |
|
00156-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
|
|
Description: HCV NS4 1916-1947aa recombinant antigen. |
 HCV NS5 2061-2302aa recombinant antigen |
|
00157-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
|
|
Description: HCV NS5 2061-2302aa recombinant antigen. |
HCV NS5 2061-2302aa recombinant antigen |
|
00157-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
|
|
Description: HCV NS5 2061-2302aa recombinant antigen. |
 HCV NS5 2212-2313aa recombinant antigen |
|
00158-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
|
|
Description: HCV NS5 2212-2313aa recombinant antigen. Available genotypes: 1a, 1b, 2a, 2b, 3a, 3b, 4, 5, 6a. |
HCV NS5 2212-2313aa recombinant antigen |
|
00158-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
|
|
Description: HCV NS5 2212-2313aa recombinant antigen. Available genotypes: 1a, 1b, 2a, 2b, 3a, 3b, 4, 5, 6a. |
 HSP70 Antigen |
|
E6TA00104 |
EnoGene |
0.1mg |
EUR 411.6 |
 CD133 Antigen |
|
E6TA00105 |
EnoGene |
0.1mg |
EUR 411.6 |
 CD32a Antigen |
|
E6TA00106 |
EnoGene |
0.1mg |
EUR 411.6 |
 CA242 Antigen |
|
E62C00601 |
EnoGene |
50KU |
EUR 2078.4 |
CA242 Antigen |
|
E62C00602 |
EnoGene |
10KU |
EUR 458.4 |
 CA199 Antigen |
|
E62C007 |
EnoGene |
10KU |
EUR 458.4 |
CA199 Antigen |
|
E62C00701 |
EnoGene |
50KU |
EUR 1180.8 |
CA199 Antigen |
|
E62C00702 |
EnoGene |
50KU |
EUR 1620 |
 CA125 Antigen |
|
E62C011 |
EnoGene |
10KU |
EUR 458.4 |
 CA153 Antigen |
|
E62C012 |
EnoGene |
10KU |
EUR 458.4 |
 EpCAM Antigen |
|
E64B00107 |
EnoGene |
0.1mg |
EUR 411.6 |
 HCV core 2-119aa recombinant antigen |
|
00150-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
|
|
Description: HCV core 2-119aa recombinant antigen. Genotypes available: 1a, 1b, 2a, 2b, 3a, 3b, 3/10, 4, 5, 6a |
HCV core 2-119aa recombinant antigen |
|
00150-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
|
|
Description: HCV core 2-119aa recombinant antigen. Genotypes available: 1a, 1b, 2a, 2b, 3a, 3b, 3/10, 4, 5, 6a |
) Cancer Antigen CEA Antigen (Human Metastatic Liver) |
|
VAng-Wyb8645-inquire |
Creative Biolabs |
inquire |
Ask for price |
|
Description: Carcinoembryonic Antigen, Antigen Grade, Cancer antigen from Human Metastatic Liver, 5.5 mg/mL. |
 S100BB Antigen |
|
E62B00201 |
EnoGene |
20ug |
EUR 458.4 |
S100BB Antigen |
|
E62B00202 |
EnoGene |
20ug |
EUR 458.4 |
, antigen grade) Gastrointestinal Cancer Antigen (CA 19-9), antigen grade |
|
CA1991-N-10 |
Alpha Diagnostics |
10 KU |
EUR 634.8 |
) Cancer Antigen 15-3 MUC 1 Antigen (Human Milk) |
|
VAng-Cr3871-10kU |
Creative Biolabs |
10 kU |
EUR 505.2 |
|
Description: Cancer Antigen 15-3 MUC 1 Antigen, Host/Source: Human Milk. The purity is detected by salt extraction and delipidization following high speed centrifugation. It is tested negative for HBsAg, antibodies to HCV and HIV 1/2. |
) Cancer Antigen CA-125 Antigen (Human Adenocarcinoma) |
|
VAng-Wyb8642-inquire |
Creative Biolabs |
inquire |
Ask for price |
|
Description: CA-125, Calibrator Grade, Cancer antigen from Human Adenocarcinoma, 500 kIU / mL. |
 S100A1B Antigen |
|
E62B00101 |
EnoGene |
20ug |
EUR 458.4 |
 S100A1B Antigen |
|
E62B00102 |
EnoGene |
20ug |
EUR 458.4 |
 Insulin Antigen |
|
E64I001 |
EnoGene |
1mg |
EUR 418.8 |
Insulin Antigen |
|
IM121 |
Cygnus Technologies |
1 ml |
EUR 342 |
|
|
|
Description: Insulin Antigen by Cygnus Technologies is available in Europe via Gentaur. |
 Giardia Trophozoite Recombinant antigen antigen 34 kDa |
|
00321-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
|
|
Description: Giardia Trophozoite Recombinant antigen antigen 34 kDa a.a. 21-280 |
Giardia Trophozoite Recombinant antigen antigen 34 kDa |
|
00321-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
|
|
Description: Giardia Trophozoite Recombinant antigen antigen 34 kDa a.a. 21-280 |
 Ferritin Antigen |
|
E62C013 |
EnoGene |
100ug |
EUR 458.4 |
Ferritin Antigen |
|
E62C01304 |
EnoGene |
100ug |
EUR 458.4 |
 Copeptin antigen |
|
E64C01601 |
EnoGene |
100ug |
EUR 411.6 |
 Inactivated Coxsackievirus A16 Antigen |
|
VAng-Lsx0079-1mL |
Creative Biolabs |
1 mL |
EUR 700.8 |
|
Description: Coxsackievirus A16, natural antigen. |
) Cancer Antigen AFP Antigen (Human hepatocellular carcinoma) |
|
VAng-Wyb8625-inquire |
Creative Biolabs |
inquire |
Ask for price |
|
Description: Alpha Fetoprotein, Antigen Grade, Cancer antigen from human hepatocellular carcinoma, 2.93 mg/mL. |
 Enterovirus Antigen |
|
30-1984 |
Fitzgerald |
1 mg |
EUR 855.6 |
|
Description: Enterovirus Protein |
 Hydrocodone Antigen |
|
VAng-Cr3693-1mg |
Creative Biolabs |
1 mg |
EUR 967.2 |
|
Description: Hydrocodone Antigen, matched pairs: JP101, JP102 or JP103 (detection); Used for ELISA, Lateral Flow. |
 (High purity)) Cancer Antigen 19-9 Antigen (Liver Carcinoma) (High purity) |
|
VAng-Cr3874-25kU |
Creative Biolabs |
25 kU |
EUR 1033.2 |
|
Description: Cancer Antigen 19-9 Antigen, Host/Source: Liver Carcinoma. |
 Antibody) Sperm Associated Antigen 11A (SPAG11A) Antibody |
|
abx238139-100ug |
Abbexa |
100 ug |
EUR 661.2 |
|
|
Sperm Associated Antigen 11A (SPAG11A) Antibody |
|
20-abx124930 |
Abbexa |
|
|
|
|
Sperm Associated Antigen 11A (SPAG11A) Antibody |
|
20-abx115757 |
Abbexa |
|
|
|
|
Sperm Associated Antigen 11A (SPAG11A) Antibody |
|
abx025940-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
|
Sperm Associated Antigen 11A (SPAG11A) Antibody |
|
abx025940-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
|
 Thyroglobulin Antigen |
|
VAng-Cr3893-1mg |
Creative Biolabs |
1 mg |
EUR 604.8 |
|
Description: Thyroglobulin Antigen, Host/Source: Human Thyroid Tissue. The purity is> 95% by SDS-PAGE. |
) RV Antigen (E1) |
|
E61Y00101 |
EnoGene |
1mg |
EUR 840 |
) Cancer Antigen 15-3 MUC 1 Antigen (Human Ascites Fluid) |
|
VAng-Cr3872-10kU |
Creative Biolabs |
10 kU |
EUR 1363.2 |
|
Description: Cancer Antigen 15-3 MUC 1 Antigen, Host/Source: Human Ascites Fluid. |
 IL-2 antigen |
|
E6IE600106 |
EnoGene |
20ug |
EUR 411.6 |
 IL-4 antigen |
|
E6IE600107 |
EnoGene |
20ug |
EUR 411.6 |
 IL-6 antigen |
|
E6IE600108 |
EnoGene |
20ug |
EUR 411.6 |
IL-2 antigen |
|
E6L00106 |
EnoGene |
20ug |
EUR 458.4 |
IL-4 antigen |
|
E6L00107 |
EnoGene |
20ug |
EUR 458.4 |
IL-6 antigen |
|
E6L00108 |
EnoGene |
20ug |
EUR 458.4 |
 SS-A Antigen |
|
E61A00301 |
EnoGene |
1mg |
EUR 1230 |
 SS-B Antigen |
|
E61A00401 |
EnoGene |
1mg |
EUR 1230 |
 Carcinoembryonic Antigen |
|
VAng-Cr3879-1mg |
Creative Biolabs |
1 mg |
EUR 1363.2 |
|
Description: Carcinoembryonic Antigen, Host/Source: Human Liver Carcinoma. The purity is> 95% by SDS-PAGE. |
 HP VacA Antigen |
|
E61H01206 |
EnoGene |
100ug |
EUR 411.6 |
 HP HSPA Antigen |
|
E61H01208 |
EnoGene |
100ug |
EUR 411.6 |
 HP RdxA Antigen |
|
E61H01209 |
EnoGene |
100ug |
EUR 411.6 |
 HP CagA Antigen |
|
E61H01210 |
EnoGene |
100ug |
EUR 411.6 |
 TB ESAT antigen |
|
E61H01301 |
EnoGene |
100ug |
EUR 458.4 |
) ToX Antigen (ROP) |
|
E61Y00303 |
EnoGene |
1mg |
EUR 840 |
 CK-MB Antigen |
|
E64C00702 |
EnoGene |
100ug |
EUR 1620 |
 CK-MM Antigen |
|
E64C00703 |
EnoGene |
100ug |
EUR 1620 |
 B19 VP1 Antigen |
|
E64H001 |
EnoGene |
100ug |
EUR 458.4 |
 Antibody) HL-60 Antigen / Human Leukemia Antigen (IPO-M6) Antibody |
|
BNC470228-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against HL-60 Antigen / Human Leukemia Antigen (IPO-M6),CF647 conjugate, Concentration: 0.1mg/mL |
The look at highlights the have an effect on of DNA polymorphisms on the pathophysiology of medical strains and provides insights into underlying mechanisms that drive signal transduction in pathogenic micro organism.
